cleveland.comAbeona Therapeutics announces new gene therapy facility, stock offeringcleveland.comAbeona Therapeutics is a clinical-stage biopharmaceutical company developing gene and cell therapies for life-threatening rare genetic diseases. Its strate… Continue reading
Thorold News |
Bluebird marks progress on Lentiglobin gene therapy
BioPharma Dive New data on Bluebird Bio Inc.’s gene therapy for sickle cell disease suggest manufacturing changes made last fall are boosting the treatment’s potency, although investors looking for more conclusive evidence of improvement will have to wait until later … bluebird bio Reports Third Quarter 2017 Financial Results and Recent Operational ProgressBusiness Wire (press release) bluebird bio to Present New Data from Clinical Studies of LentiGlobinTM Gene Therapy in Transfusion-Dependent β …Digital Journal bluebird bio (BLUE) Earns Daily Media Sentiment Score of 0.08StockNewsTimes Weekly Register all 31 news articles » |
Endpoints News |
California upstart Xyphos wants to tackle CAR–T’s big problems
Endpoints News If, however, the cancer patient begins experiencing toxicity, the doctor could stop the antibody therapy. The antibody then cycles out of the patient, and the CARs revert to harmless, inactive T cells. Its sort of like switching T cells on and off when … AvidBiotics Splits into Two Biotechnology Companies Each Developing its Distinct Technology PlatformPR Newswire (press release) |
Genetic Literacy Project |
Safer CRISPR? Cas13 version edits RNA, not DNA
Genetic Literacy Project In a paper published in Science, researchers described an entirely new CRISPR-based gene editing tool that targets RNA, DNA’s sister, allowing for transient changes to genetic material. In Nature, scientists described how a more refined type of CRISPR … Viewpoint: European anti-tech groups threaten to derail CRISPR gene editing in agricultureGrain Central (blog) |
|
Collaboration to Develop Gene Therapies Delivery
Labmate Online A research collaboration is to assess the effectiveness of developing gene therapies using Avacta Group’s Affimer technology combined with FIT Biotech Oy’s gtGTU® platform. The very small, simply structured Affirmer proteins have ideal potential for … |